Viking Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $694.00 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Viking Therapeutics Inc had its IPO on 2015-04-29 under the ticker symbol VKTX.
The company operates in the Healthcare sector and Biotechnology industry. Viking Therapeutics Inc has a staff strength of 21 employees.
Shares of Viking Therapeutics Inc opened at $9.21 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $8.68 - $9.31, and closed at $8.85.
This is a -4.12% slip from the previous day's closing price.
A total volume of 2,566,251 shares were traded at the close of the day’s session.
In the last one week, shares of Viking Therapeutics Inc have slipped by -19.1%.
Viking Therapeutics Inc's Key Ratios
Viking Therapeutics Inc has a market cap of $694.00 million, indicating a price to book ratio of 1.8654 and a price to sales ratio of 0.
In the last 12-months Viking Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Viking Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Viking Therapeutics Inc’s operating margin was 0% while its return on assets stood at -23.19% with a return of equity of -39.67%.
In Q4, Viking Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Viking Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.03. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Viking Therapeutics Inc’s profitability.
Viking Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.0683. Its price to sales ratio in the trailing 12-months stood at 0.
Viking Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $168.53 million
- Total Liabilities
- $21.95 million
- Operating Cash Flow
- $7.26 million
- Capital Expenditure
- Dividend Payout Ratio
Viking Therapeutics Inc ended 2023 with $168.53 million in total assets and $0 in total liabilities. Its intangible assets were valued at $168.53 million while shareholder equity stood at $145.32 million.
Viking Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $21.95 million in other current liabilities, 1000.00 in common stock, $-292049000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $36.63 million and cash and short-term investments were $155.49 million. The company’s total short-term debt was $304,000 while long-term debt stood at $0.
Viking Therapeutics Inc’s total current assets stands at $167.04 million while long-term investments were $0 and short-term investments were $118.85 million. Its net receivables were $0 compared to accounts payable of $8.53 million and inventory worth $0.
In 2023, Viking Therapeutics Inc's operating cash flow was $7.26 million while its capital expenditure stood at $0.
Comparatively, Viking Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Viking Therapeutics Inc stock is currently trading at $8.85 per share. It touched a 52-week high of $11.985 and a 52-week low of $11.985. Analysts tracking the stock have a 12-month average target price of $19.22.
Its 50-day moving average was $10.13 and 200-day moving average was $5.48 The short ratio stood at 2.55 indicating a short percent outstanding of 0%.
Around 1068.4% of the company’s stock are held by insiders while 4470.5% are held by institutions.
Frequently Asked Questions About Viking Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.